证券日报网讯 蓝帆医疗10月9日在互动平台回答投资者提问时表示，基于公司转债条款和目前股价，现 阶段仅靠转股价格下修确实无法从根本上解决问题，还需要合适的市场条件、股价进一步修复。公司极 其重视可转债兑付事项，在积极推进正股估值提升的同时，除审慎用好公司现有货币资金外，也在通过 经营性、融资性现金流等多措并举进一步增强资金实力，正在逐步落实举措。2024年以来公司有多个战 略融资事项落地，体现了公司盘活资产负债表、明显提升账上现金的潜力和能力。公司正在逐步落实一 系列举措，触及公告节点将及时进行公告。 （编辑 袁冠琳） ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-082 | | --- | --- | --- | | | 债券简称：蓝帆转债 | | | 债券代码：128108 | | | 蓝帆医疗股份有限公司 关于2025年第三季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 证券代码：002382，证券简称：蓝帆医疗 债券代码：128108，债券简称：蓝帆转债 转股价格：人民币 12.50 元/股、12.00 元/股（2025 年 7 月 8 日生效）、11.50 元/股 （2025 年 8 月 15 日生效）、10.50 元/股（2025 年 9 月 23 日生效） 转股时间：2020 年 12 月 3 日至 2026 年 5 月 27 日 根据《深圳证券交易所股票上市规则》、《深圳证券交易所可转换公司债券交易 实施细则》的有关规定，蓝帆医疗股份有限公司（以下简称"公司"）现将2025 年第三季 度可转换公司债券（以下简称"可转债"）转股及公司股份变动情况公告如下： 一、可转债发行上市基本情况 （一）可转 ...

Core Viewpoint - The company, Bluestar Medical (002382.SZ), confirmed that it will not participate in the 11th batch of centralized drug procurement organized by the state, as it does not involve the company's products. Instead, the company is actively participating in the 6th batch of high-value medical consumables procurement organized by the state [1]. Group 1 - The 11th batch of centralized procurement will be held on October 21 in Shanghai [1]. - The company is not involved in the 11th batch of centralized drug procurement [1]. - The company is actively participating in the 6th batch of high-value medical consumables procurement [1].

Core Viewpoint - The company, Bluefan Medical, has an annual production capacity of approximately 50 billion medical gloves and is adjusting its production strategy in response to the current market conditions, which have led to historically low prices for disposable gloves [1]. Group 1: Production Capacity - Bluefan Medical's annual production capacity for health protective gloves is about 50 billion units [1]. Group 2: Market Conditions - The prices of disposable gloves have dropped to historical lows this year due to the impact of international trade conditions [1]. - The company plans to adopt a flexible production strategy, including a reduction in output to stabilize prices and help increase the average market price, aiming to gradually emerge from the current price trough [1].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-081 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 蓝帆医疗股份有限公司（以下简称"公司"或"本公司"）于近日接到控股股东 淄博蓝帆投资有限公司（以下简称"蓝帆投资"）的通知，获悉蓝帆投资将其持有的 本公司部分股份办理了解除质押及再质押手续，具体情况如下： 上述股份的质押情况，详见公司于 2024 年 6 月 19 日披露在指定信息媒体的《关 于控股股东部分股份解除质押及再质押的公告》（公告编号：2024-064），于 2024 年 12 月 27 日披露在指定信息媒体的《关于控股股东部分股份解除质押及再质押的公告》（公 告编号：2024-110）。 二、股东股份质押基本情况 1、本次股份质押基本情况 股东 名称 是否为控 股股东或 第一大股 东及其一 致行动人 本次解除质押 股份数量（股） 占其所 持股份 比例 ...

Core Viewpoint - The company, BluFan Medical, has decided to lower the conversion price of its convertible bonds due to the stock price being below the previous conversion price for a significant period, indicating a strategic adjustment in response to market conditions [1][2]. Trading Information Summary - As of September 22, 2025, BluFan Medical's stock closed at 5.7 yuan, down 1.04%, with a turnover rate of 0.68% and a trading volume of 67,900 shares, amounting to a transaction value of 38.77 million yuan [1]. - On the same day, the net outflow of funds from major investors was 5.55 million yuan, while retail investors saw a net inflow of 5.88 million yuan [3]. Company Announcement Summary - The sixth board of directors of BluFan Medical held a meeting on September 22, 2025, where it was resolved to lower the conversion price of the "BluFan Convertible Bonds" from 11.50 yuan per share to 10.50 yuan per share, effective from September 23, 2025 [2]. - This adjustment was triggered as the stock price had been below 85% of the conversion price for at least 15 out of the last 30 trading days [2].

Group 1 - The article discusses the upcoming IPOs and their details, including the issuance price and market capitalization [1] - It highlights the strategic partnership between Lepu Medical and Hanhai Information Technology, focusing on market promotion and operations in the medical aesthetics sector [1] - The article mentions the collaboration between Tianci Materials and Ruipu Lanjun, indicating a potential growth opportunity [1] Group 2 - The article provides information on convertible bonds, including their current prices, redemption prices, and last trading dates [3][6] - It lists various convertible bonds with their respective market values and conversion ratios, indicating the financial health and market positioning of the companies involved [3][6] - The article emphasizes the importance of monitoring convertible bond performance as part of investment strategies [6]

Group 1 - The company announced that it will hold the 30th meeting of the 6th Board of Directors on September 22, 2025 [2] - The meeting will review the proposal to adjust the conversion price of "Bluefan Convertible Bonds" [2]

Core Viewpoint - Bluefan Medical (002382) has experienced a decline in stock price and financial performance, indicating potential challenges in the medical device industry [1][2]. Financial Performance - As of September 22, 2025, Bluefan Medical's stock closed at 5.7 yuan, down 1.04%, with a trading volume of 67,900 hands and a transaction amount of 38.77 million yuan [1]. - The company's total revenue for the first half of 2025 was 2.781 billion yuan, a year-on-year decrease of 7.49% [2]. - The net profit attributable to shareholders was -135 million yuan, a year-on-year increase of 15.88% [2]. - The second quarter of 2025 saw a single-quarter revenue of 1.303 billion yuan, down 16.0% year-on-year, and a net profit of -212 million yuan, a decrease of 245.53% year-on-year [2]. Market Position - Bluefan Medical's total market capitalization is 5.741 billion yuan, significantly lower than the industry average of 11.909 billion yuan, ranking 61 out of 123 in the medical device sector [2]. - The company has a net asset value of 9.905 billion yuan, which is higher than the industry average of 3.889 billion yuan, ranking 7 out of 123 [2]. - The company's price-to-earnings ratio is -21.3, while the industry average is 64.67, indicating a challenging profitability outlook [2]. Profitability Metrics - Bluefan Medical's gross margin is 14.34%, significantly lower than the industry average of 51.85%, ranking 120 out of 123 [2]. - The net profit margin stands at -5.14%, compared to the industry average of 10.39%, ranking 106 out of 123 [2]. - The return on equity (ROE) is -1.66%, while the industry average is 1.8%, ranking 112 out of 123 [2]. Capital Flow - On September 22, 2025, the net outflow of main funds was 5.551 million yuan, accounting for 14.32% of the total transaction amount [1]. - Retail investors showed a net inflow of 5.8796 million yuan, representing 15.16% of the total transaction amount on the same day [1].

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-080 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 蓝帆医疗股份有限公司（以下简称"公司"）于 2025 年 9 月 22 日召开第六届董事 会第三十次会议，审议通过了《关于向下修正"蓝帆转债"转股价格的议案》，现将相 关事项公告如下： 一、可转债发行上市基本情况 （一）可转债发行情况 经中国证券监督管理委员会"证监许可〔2020〕710 号"文核准，公司于 2020 年 5 月 28 日公开发行了3,144.04 万张可转换公司债券（以下简称"可转债"），每张面值100 元，发 行总额314,404 万元。 （二）可转债上市情况 经深圳证券交易所（以下简称"深交所"）"深证上〔2020〕523 号"文同意，公司 314,404 万元可转债于 2020 年 6 月 19 日起在深交所挂牌交易，债券简称"蓝帆 ...